Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORIC Oric Pharmaceuticals Inc.

Trading 07-10 10:19:43 EDT

10.42

-0.52

-4.75%

High11.17	Low10.41	Vol88.48K
Open11.04	D1 Closing10.94	Amplitude6.90%
Mkt Cap1.08B	Tradable Cap861.91M	Total Shares103.52M
T/O941.20K	T/O Rate0.11%	Tradable Shares82.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":10.42,"timestamp":1783693181216,"preClose":10.94,"halted":0,"volume":88480,"delay":0,"changeRate":-0.047531992687385706,"floatShares":82717200,"shares":103517562,"eps":-1.402607,"marketStatus":"Trading","change":-0.52,"latestTime":"07-10 10:19:43 EDT","open":11.04,"high":11.165,"low":10.41,"amount":941199.9833600001,"amplitude":0.069013,"askPrice":10.44,"askSize":200,"bidPrice":10.42,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.402607,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783713600000},"marketStatusCode":2,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":10.94,"preHourTrading":{"tag":"盘前","latestPrice":11.05,"preClose":10.94,"latestTime":"09:29 EDT","volume":1704,"amount":18612.832896,"timestamp":1783690199999,"change":0.11,"changeRate":0.010055,"amplitude":0.031993},"postHourTrading":{"tag":"盘后","latestPrice":10.73,"preClose":10.94,"latestTime":"17:47 EDT","volume":11737,"amount":127861.04,"timestamp":1783633629446,"change":-0.21,"changeRate":-0.019196,"amplitude":0.019196},"volumeRatio":0.33469,"impliedVol":1.6305,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/ORIC/wiki","defaultTab":"wiki","newsList":[{"id":"2650916599","title":"Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600","url":"https://stock-news.laohu8.com/highlight/detail?id=2650916599","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650916599?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:36","pubTimestamp":1783542967,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals director Richard A. Heyman sells 300 shares for $3,600Oric Pharmaceuticals director Richard A. Heyman disposed of 300 common shares on July 6 at $12.Indirect common stock holdings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL7HL6Fs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648636544","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648636544","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648636544?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:30","pubTimestamp":1783024200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO and SAN DIEGO, July  02, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechani","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321570/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645831890","title":"Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645831890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645831890?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300628,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-biomea-fusion-bmea-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oric-pharmaceuticals-oric-biomea-fusion-bmea-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","HCSG","BK4585","LU0128526141.USD","BK4581","ORIC","BK4139","BK4082","BK4588","LU0029874061.USD","BMEA","SENS","XLV","BK4137","BK4539","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008853","title":"Oric Shareholders Approve Equity Plan, Governance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008853?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:00","pubTimestamp":1782162059,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals ( ($ORIC) ) just unveiled an announcement. On June 18, 2026, ORIC Pharmaceuticals’ shareholders approved an amended and restat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oric-shareholders-approve-equity-plan-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oric-shareholders-approve-equity-plan-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4139","ORIC","BK4215","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645771070","title":"Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645771070","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645771070?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:06","pubTimestamp":1782158767,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals held its annual shareholder meeting on June 18, 2026.Holders backed an annual cadence for future advisory votes on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLlPCKL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642262069","title":"Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2642262069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642262069?lang=en_us&edition=fundamental","pubTime":"2026-06-12 18:55","pubTimestamp":1781261730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K01A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286604","title":"Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286604?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:50","pubTimestamp":1781175045,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE). Om...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omnicell-omcl-oric-pharmaceuticals-oric-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-omnicell-omcl-oric-pharmaceuticals-oric-and-pfizer-pfe-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4007","BK4139","IE00B19Z3B42.SGD","ORIC","OMCL","LU0225284248.USD","LU0456855351.SGD","BK4533","LU0122379950.USD","IE0002270589.USD","LU0289739699.SGD","BK4167","IE00BLSP4452.SGD","BK4588","LU1883839398.USD","PFE","SG9999002224.SGD","LU0321505439.SGD","BK4581","LU0306806265.USD","SG9999011175.SGD","LU1057294990.SGD","BK4082","BK4550","LU0868494617.USD","BK4568","LU1894683348.USD","LU0985481810.HKD","IE00BLSP4239.USD","BK4534","BK4592","LU0306807586.USD","LU1023059063.AUD","LU1066051498.USD","LU1066053197.SGD","SG9999001176.USD","SG9999013999.USD","LU0225771236.USD","LU0234572021.USD","BK4599","SG9999003800.SGD","LU0321505868.SGD","SG9999001176.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","SG9999002232.USD","IE00B3T34201.USD","LU0170899867.USD","LU0058720904.USD","LU2596442595.SGD","BK4585","LU1894683264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641852234","title":"Analyst Reiterates Buy on ORIC as Share Price Pullback Creates Opportunity; $25 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2641852234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641852234?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:36","pubTimestamp":1780914964,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-oric-as-share-price-pullback-creates-opportunity-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-oric-as-share-price-pullback-creates-opportunity-25-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485979","title":"Oric Pharmaceuticals Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641485979?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:33","pubTimestamp":1780914780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:33 ET (10:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140834","title":"Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140834?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:30","pubTimestamp":1780691400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nTUA57CMZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140315","title":"ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140315","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140315?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:30","pubTimestamp":1780691400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June  05, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307620/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904179","title":"Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640904179?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:40","pubTimestamp":1780490412,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ardent Health Partners, Inc. (ARDT), Tactile Systems...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ardent-health-partners-inc-ardt-tactile-systems-technology-tcmd-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ardent-health-partners-inc-ardt-tactile-systems-technology-tcmd-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","XLV","LABU","XBI","LU0029874061.USD","HCSG","BK4185","BK4082","TCMD","BK4137","BK4581","BK4585","ARDT","ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638636780","title":"ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638636780","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638636780?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:05","pubTimestamp":1779912300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  27, 2026  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3302364/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633942529","title":"Oric Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2633942529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633942529?lang=en_us&edition=fundamental","pubTime":"2026-05-06 00:04","pubTimestamp":1777997040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ORIC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2026 12:04 ET (16:04 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633485819","title":"ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2633485819","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633485819?lang=en_us&edition=fundamental","pubTime":"2026-05-05 20:15","pubTimestamp":1777983322,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading maintained a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Boris Pe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/oric-pharmaceuticals-buy-rating-backed-by-advancing-oncology-pipeline-phase-3-prostate-cancer-trial-and-2026-nsclc-data-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591790","title":"Piper Sandler Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591790","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591790?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:38","pubTimestamp":1777981083,"startTime":"0","endTime":"0","summary":"In a report released today, Kelsey Goodwin from Piper Sandler maintained a Buy rating on Oric Pharmaceuticals, with a price target of $22.00. Goodw...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991212","title":"Guggenheim Remains a Buy on Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991212?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979912,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Bradley Canino reiterated a Buy rating on Oric Pharmaceuticals yesterday and set a price target of $18.00. The company’s shares ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-oric-pharmaceuticals-oric-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633124969","title":"Oric Pharmaceuticals (ORIC) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2633124969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633124969?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:18","pubTimestamp":1777979888,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo reiterated a Buy rating on Oric Pharmaceuticals, with a price target of $25.00. Archila ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oric-pharmaceuticals-oric-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0072461881.USD","LU1201861249.SGD","LU0130517989.USD","LU0683600562.USD","IE0002270589.USD","LU2361044949.HKD","LU1280957306.USD","LU0211327993.USD","LU0942090050.USD","LU0052756011.USD","LU0175139822.USD","LU1035773651.USD","LU2361045086.USD","LU1069347547.HKD","LU0128525689.USD","LU0211328371.USD","LU0310800379.SGD","LU0208291251.USD","LU0314106906.USD","IE00B7SZLL34.SGD","LU0980610538.SGD","LU1267930490.SGD","LU1814569148.SGD","LU0289960550.SGD","LU0971096721.USD","ORIC","BK4588","IE00B19Z3581.USD","LU0708994859.HKD","LU1894683264.USD","LU2361044865.SGD","BK4559","IE00B19Z3B42.SGD","LU0149725797.USD","LU0256863811.USD","LU0868494617.USD","LU1894683348.USD","LU0029864427.USD","LU1791807156.HKD","LU0251131958.USD","BK4139","LU0162691827.USD","LU0868494708.USD","BK4585","LU1363072403.SGD","BK4207","LU0128525929.USD","LU0310800965.SGD","LU0130102774.USD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633775919","title":"Oric Pharmaceuticals price target lowered to $16 from $17 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2633775919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633775919?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:39","pubTimestamp":1777977589,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares. Published first on TheFly...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oric-pharmaceuticals-price-target-lowered-to-16-from-17-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966410","title":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966410?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926658,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryOric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 34 cents per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H291:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.0601},{"period":"1month","weight":0.3675},{"period":"3month","weight":0.0778},{"period":"6month","weight":0.1956},{"period":"1year","weight":0.0037},{"period":"ytd","weight":0.3374}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":0.0199},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.083},{"period":"1year","weight":0.2045},{"period":"ytd","weight":0.1023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.047029},{"month":6,"riseRate":0.714286,"avgChangeRate":0.161131},{"month":7,"riseRate":0.428571,"avgChangeRate":0.001013},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oric Pharmaceuticals Inc.(ORIC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction